Adaptive clinical trial designs in oncology.

Adaptive designs have become popular in clinical trial and drug development. Unlike traditional trial designs, adaptive designs use accumulating data to modify the ongoing trial without undermining the integrity and validity of the trial. As a result, adaptive designs provide a flexible and effective way to conduct clinical trials. The designs have potential advantages of improving the study power, reducing sample size and total cost, treating more patients with more effective treatments, identifying efficacious drugs for specific subgroups of patients based on their biomarker profiles, and shortening the time for drug development. In this article, we review adaptive designs commonly used in clinical trials and investigate several aspects of the designs, including the dose-finding scheme, interim analysis, adaptive randomization, biomarker-guided randomization, and seamless designs. For illustration, we provide examples of real trials conducted with adaptive designs. We also discuss practical issues from the perspective of using adaptive designs in oncology trials.

[1]  M A Proschan,et al.  Designed extension of studies based on conditional power. , 1995, Biometrics.

[2]  S. Piantadosi.  Clinical Trials : A Methodologic Perspective , 2005 .

[3]  Donald A. Berry,et al.  Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development , 2009 .

[4]  G. Yin,et al.  Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization , 2012, Clinical Cancer Research.

[5]  A review of phase II trial designs for initial marker validation. , 2013, Contemporary clinical trials.

[6]  Janet Woodcock,et al.  FDA introductory comments: clinical studies design and evaluation issues , 2005, Clinical trials.

[7]  Boris Freidlin,et al.  Randomized clinical trials with biomarkers: design issues. , 2010, Journal of the National Cancer Institute.

[8]  Ying Yuan,et al.  Adaptive designs for identifying optimal biological dose for molecularly targeted agents , 2014, Clinical trials.

[9]  P. Thall,et al.  Practical Bayesian adaptive randomisation in clinical trials. , 2007, European journal of cancer.

[10]  Jeffrey R. Eisele.  The doubly adaptive biased coin design for sequential clinical trials , 1994 .

[11]  F. Ellis.  International Symposium on Hodgkin's Disease , 1974 .

[12]  G. Sledge,et al.  What is targeted therapy? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Richard Simon,et al.  The Use of Genomics in Clinical Trial Design , 2008, Clinical Cancer Research.

[14]  J O'Quigley,et al.  Dose‐Finding Designs for HIV Studies , 2001, Biometrics.

[15]  D. Berry.  Adaptive clinical trials in oncology , 2012, Nature Reviews Clinical Oncology.

[16]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.

[17]  D. Sargent,et al.  Issues in clinical trial design for tumor marker studies. , 2002, Seminars in oncology.

[18]  S. Pocock.  Group sequential methods in the design and analysis of clinical trials , 1977 .

[19]  Thomas Jaki,et al.  Some recommendations for multi-arm multi-stage trials , 2012, Statistical methods in medical research.

[20]  Guosheng Yin,et al.  Clinical Trial Design: Bayesian and Frequentist Adaptive Methods , 2011 .

[21]  Y K Cheung,et al.  Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.

[22]  T. Chen,et al.  Optimal two-stage designs for phase ii clinical trials with differentiation of complete and partial responses , 2000 .

[23]  S. Pocock,et al.  Clinical Trials: A Practical Approach , 1984 .

[24]  P F Thall,et al.  Practical Bayesian guidelines for phase IIB clinical trials. , 1994, Biometrics.

[25]  M. Krams,et al.  Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group , 2006, Journal of biopharmaceutical statistics.

[26]  Peter F Thall,et al.  Monitoring event times in early phase clinical trials: some practical issues , 2005, Clinical trials.

[27]  Ying Kuen Cheung,et al.  Two‐Stage Designs for Dose‐Finding Trials with a Biologic Endpoint Using Stepwise Tests , 2008, Biometrics.

[28]  Ying Yuan,et al.  Bayesian dose finding in oncology for drug combinations by copula regression , 2009 .

[29]  W. Bischoff,et al.  A Seamless Phase II/III Design with Sample-Size Re-Estimation , 2009, Journal of biopharmaceutical statistics.

[30]  J Jack Lee,et al.  A predictive probability design for phase II cancer clinical trials , 2008, Clinical trials.

[31]  Daniel J Sargent,et al.  Clinical trial designs for predictive marker validation in cancer treatment trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Antje Hoering,et al.  Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents , 2010, Clinical Cancer Research.

[33]  R. Simon,et al.  Biomarker based clinical trial design. , 2014, Chinese clinical oncology.

[34]  Ying Yuan,et al.  Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes , 2009 .

[35]  A. Tsiatis,et al.  Approximately optimal one-parameter boundaries for group sequential trials. , 1987, Biometrics.

[36]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[37]  Nigel Stallard,et al.  A confirmatory seamless phase II/III clinical trial design incorporating short‐term endpoint information , 2010, Statistics in medicine.

[38]  J. Wason,et al.  A comparison of Bayesian adaptive randomization and multi‐stage designs for multi‐arm clinical trials , 2014, Statistics in medicine.

[39]  D L DeMets,et al.  Interim analysis: the alpha spending function approach. , 1994, Statistics in medicine.

[40]  B. Efron.  International Symposium on Hodgkin's Disease. Session 6. Survival data and prognosis. Invited discussion: Forcing a sequential experiment to be balanced. , 1973, National Cancer Institute monograph.

[41]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[42]  Shein-Chung Chow,et al.  Adaptive design methods in clinical trials – a review , 2008, Orphanet journal of rare diseases.

[43]  D. Faries,et al.  Practical modifications of the continual reassessment method for phase I cancer clinical trials. , 1994, Journal of biopharmaceutical statistics.

[44]  R. Simon,et al.  On the efficiency of targeted clinical trials , 2005, Statistics in medicine.

[45]  R Simon,et al.  Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.

[46]  Constantine Gatsonis,et al.  Case Studies in Bayesian Statistics: Volume III , 1997 .

[47]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[48]  Carrie Printz.  I‐SPY 2 breast cancer clinical trial launches nationwide , 2010 .

[49]  S. Goodman,et al.  Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.

[50]  P. Thall,et al.  Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs , 2004, Biometrics.

[51]  Feifang Hu,et al.  Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials , 2003 .

[52]  A. Tsiatis,et al.  On the inefficiency of the adaptive design for monitoring clinical trials , 2003 .

[53]  J. Kumagai.  Quantum leap , 2009 .

[54]  N. Schork,et al.  The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? , 2011, Personalized medicine.

[55]  N Stallard,et al.  Optimal Adaptive Designs for Binary Response Trials , 2001, Biometrics.

[56]  Michael D. Smith,et al.  Adaptive Bayesian Designs for Dose-Ranging Drug Trials , 2002 .

[57]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[58]  D. Berry.  Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.

[59]  Peter F Thall,et al.  Seamlessly Expanding a Randomized Phase II Trial to Phase III , 2002, Biometrics.

[60]  Jing Ning,et al.  Using short‐term response information to facilitate adaptive randomization for survival clinical trials , 2009, Statistics in medicine.

[61]  S Zacks,et al.  Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.

[62]  M. Parmar,et al.  Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial , 2009, Trials.

[63]  P. Thall,et al.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.

[64]  Nan Chen,et al.  Phase II trial design with Bayesian adaptive randomization and predictive probability , 2012, Journal of the Royal Statistical Society. Series C, Applied statistics.

[65]  D. Berry,et al.  I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.

[66]  Ying Yuan,et al.  Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials , 2009 .

[67]  J Jack Lee,et al.  Bayesian clinical trials in action , 2012, Statistics in medicine.

[68]  B. Freidlin,et al.  Outcome--adaptive randomization: is it useful? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  T. Braun.  The current design of oncology phase I clinical trials: progressing from algorithms to statistical models. , 2014, Chinese clinical oncology.

[70]  Xuelin Huang,et al.  A Parallel Phase I/II Clinical Trial Design for Combination Therapies , 2007, Biometrics.

[71]  L. J. Wei,et al.  The Randomized Play-the-Winner Rule in Medical Trials , 1978 .

[72]  Richard Simon,et al.  Evaluation of randomized discontinuation design. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  D. Sargent,et al.  Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications , 2012, Clinical Cancer Research.

[74]  M. Zelen,et al.  Play the Winner Rule and the Controlled Clinical Trial , 1969 .

[75]  Ying Yuan,et al.  BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY. , 2013, The annals of applied statistics.

[76]  Ying Yuan,et al.  Sequential continual reassessment method for two‐dimensional dose finding , 2008, Statistics in medicine.

[77]  Bradley P. Carlin,et al.  Bayesian Adaptive Methods for Clinical Trials , 2010 .

[78]  Edward S. Kim,et al.  Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine , 2008, Clinical trials.

[79]  D. Berry,et al.  Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials , 2012, Clinical Cancer Research.

[80]  Ying Yuan,et al.  Robust EM Continual Reassessment Method in Oncology Dose Finding , 2011, Journal of the American Statistical Association.

[81]  Cassandra Willyard.  'Basket studies' will hold intricate data for cancer drug approvals , 2013, Nature Medicine.

[82]  Daniel J Sargent,et al.  Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  P F Thall,et al.  A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. , 1998, Biometrics.

[84]  Daniel J Sargent,et al.  An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations , 2007, Statistics in medicine.

[85]  Draft Guidance.  Adaptive Design Clinical Trials for Drugs and Biologics , 2010 .

[86]  L Fisher,et al.  Statistical Inference for Self‐Designing Clinical Trials with a One‐Sided Hypothesis , 1999, Biometrics.

[87]  Ying Yuan,et al.  A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents , 2009, Biometrics.

[88]  R. Simon,et al.  Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials , 2004, Clinical Cancer Research.

[89]  E. Gehan,et al.  The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.

[90]  J Jack Lee,et al.  Bayesian adaptive randomization designs for targeted agent development , 2008, Clinical trials.

[91]  T A Gooley,et al.  Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. , 1994, Controlled clinical trials.

[92]  Mark Chang,et al.  Adaptive Design Methods in Clinical Trials , 2006 .

[93]  Nigel Stallard,et al.  Dose selection in seamless phase II/III clinical trials based on efficacy and safety , 2009, Statistics in medicine.

[94]  Peter F Thall,et al.  Dose‐Finding with Two Agents in Phase I Oncology Trials , 2003, Biometrics.

[95]  Yuan Ji,et al.  Bayesian Dose‐Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios , 2006, Biometrics.

[96]  Wei Zhang,et al.  An adaptive dose‐finding design incorporating both toxicity and efficacy , 2006, Statistics in medicine.

[97]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[98]  Daniel J Sargent,et al.  Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers , 2013, Clinical trials.